Looking for volunteers
R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma
NCT05345158 · University Health Network, Toronto · Updated 19 Dec 2025
- What is being tested
- Robotic Retroperitoneal Lymph Node Dissection (RPLND)
- For
- Lymphadenopathy Retroperitoneal; Stage II Testicular Seminoma
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years and older. About 25 people. The full rules are on the registry page.
- Where
- Canada
- When
- Starts or started 23 Feb 2022, ends Nov 2030. Registered 25 April 2022.
- Results
- None posted yet.
In the researchers' words
This study will investigate the safety and efficacy of using robotic retroperitoneal lymph node dissection (R-RPLND), a minimally invasive surgical approach, as the first-line of treatment for stage IIA/B (or equivalent) seminoma patients. R-RPLND will be trialed as an alternative to chemotherapy, radiation therapy (for seminoma patients) and open RPLND in this study.
Sites
- Princess Margaret Cancer CentreToronto, Ontario, Canada